ライフサイエンスコーパス: estrogen replacement therapy

1 beneficial effect may be prevented by use of estrogen replacement therapy.

2 th [(18)F]deuteroaltanserin before and after estrogen replacement therapy.

3 iectomized, and half of the animals received estrogen replacement therapy.

4 t recent hormonal therapy, chemotherapy, and estrogen replacement therapy.

5 s in rats with OVX that are or are not given estrogen replacement therapy.

6 cording to current use or duration of use of estrogen replacement therapy.

7 and grain intake, aspirin use and, in women, estrogen replacement therapy.

8 ults differed substantially for women taking estrogen replacement therapy.

9 reased fracture risk that can be reversed by estrogen replacement therapy.

10 17-one (equilin), an equine estrogen used in estrogen replacement therapy.

11 ng aspirin, antihypertensive medication, and estrogen-replacement therapy.

12 women who were receiving oral or transdermal estrogen-replacement therapy (44 of whom were receiving

13 Estrogen replacement therapy after first myocardial infa

14 Estrogen replacement therapy after myocardial infarction

15 isk for reinfarction associated with current estrogen replacement therapy after myocardial infarction

16 provides reassurance regarding the safety of estrogen replacement therapy after myocardial infarction

17 Estrogen replacement therapy and hormonal replacement th

18 attempted to determine the relation between estrogen replacement therapy and the rate of restenosis

19 es evaluating endogenous estrogen levels and estrogen replacement therapy and their relation to the o

20 lity as well as data on age, height, weight, estrogen replacement therapy, and menopause status were

21 Estrogen replacement therapy appears to delay the onset

22 Since estrogen replacement therapy benefits the outcome of cer

23 These results suggest a mechanism by which estrogen replacement therapy can delay or prevent AD.

24 Epidemiological studies indicate that estrogen replacement therapy decreases the risk of cardi

25 Estrogen replacement therapy enhances mood, delays cogni

26 Women using unopposed estrogen replacement therapy (ERT) (exclusive ERT use),

27 ars) were grouped according to HRT received: estrogen replacement therapy (ERT) (n = 13), combined (e

28 logic studies suggest a protective effect of estrogen replacement therapy (ERT) against the developme

29 d with EPRT is substantially higher than for estrogen replacement therapy (ERT) alone.

30 nction in 14 post-menopausal women receiving estrogen replacement therapy (ERT) and 48 post-menopausa

31 ated that women who have used postmenopausal estrogen replacement therapy (ERT) are at reduced risk o

32 ociation between endometrial cancer risk and estrogen replacement therapy (ERT) by CYP17 genotype usi

33 SND, however, has not been recorded during estrogen replacement therapy (ERT) in humans.

34 Estrogen replacement therapy (ERT) in postmenopausal wom

35 Clinical trials have shown estrogen replacement therapy (ERT) is associated with ad

36 nd, therefore, it has been hypothesized that estrogen replacement therapy (ERT) may have a role in pr

37 g-term (2 years) effects of estrogen loss or estrogen replacement therapy (ERT) on cholinergic neuron

38 umerous epidemiological studies suggest that estrogen replacement therapy (ERT) reduces cancer risk i

39 Although observational studies suggest that estrogen replacement therapy (ERT) reduces cardiovascula

40 Clinical studies have shown that estrogen replacement therapy (ERT) reduces the incidence

41 Some studies have shown that estrogen replacement therapy (ERT) relieves memory impai

42 The association of estrogen replacement therapy (ERT) with cognitive functi

43 luteal) women, older postmenopausal women on estrogen replacement therapy (ERT), and older postmenopa

44 intake after age 60 y, body weight, current estrogen replacement therapy (ERT), and past oral contra

45 Estrogen replacement therapy (ERT), composed of equileni

46 at menarche, parity, oral contraceptive use, estrogen replacement therapy (ERT), or history of oophor

47 on to the duration and the recency of use of estrogen replacement therapy (ERT), simultaneously inclu

48 h 12 postmenopausal women who were not using estrogen replacement therapy (ERT).

49 at 14 months after treatment with placebo or estrogen replacement therapy (ERT).

50 The increased incidence may be delayed by estrogen replacement therapy (ERT).

51 er users as well as by total years of use of estrogen replacement therapy (ERT).

52 We investigated whether the route of estrogen replacement therapy (ET) is the major determina

53 Estrogen replacement therapy for 1 year did not slow dis

54 disorders, and provide another rationale for estrogen replacement therapy for postmenopausal women.

55 verse effect and raise concern for long term estrogen replacement therapy for stroke prevention, thes

56 is now strong epidemiological evidence that estrogen replacement therapy has a protective effect in

57 Estrogen replacement therapy has also been shown to sign

58 onducted clinical trials have indicated that estrogen replacement therapy has an adverse effect and r

59 Although estrogen replacement therapy has been associated with re

60 These findings suggest long-term estrogen replacement therapy has effects on cardiovascul

61 Epidemiologic studies of women who take estrogen replacement therapy, however, consistently repo

62 Hormone/estrogen replacement therapy (HRT/ERT) has a positive ef

63 The importance of postmenopausal estrogen replacement therapy in affording protection aga

64 Previously, we have shown that estrogen replacement therapy in postmenopausal women dec

65 Several studies have suggested that estrogen replacement therapy in postmenopausal women imp

66 Estrogen replacement therapy in postmenopausal women is

67 raised concern for the protective effect of estrogen replacement therapy in postmenopausal women.

68 ese findings have important implications for estrogen replacement therapy in the context of aging.

69 Ovariectomized Sprague-Dawley rats received estrogen replacement therapy in the form of subcutaneous

70 or binding was significantly increased after estrogen replacement therapy in the right prefrontal cor

71 One possible outcome of estrogen replacement therapy in vivo could be reduction

72 Although estrogen replacement therapy in women has been associate

73 Estrogen replacement therapy in women is associated with

74 Female gender and estrogen-replacement therapy in postmenopausal women are

75 Estrogen replacement therapy increases plasma concentrat

76 nd clinical trials consistently suggest that estrogen replacement therapy is associated with benefici

77 In observational studies, estrogen replacement therapy is associated with decrease

78 Because estrogen replacement therapy is known to restore some im

79 t estrogen also has positive effects even if estrogen replacement therapy is not a cure-all.

80 varied significantly with ethnicity, use of estrogen replacement therapy, mammographic breast densit

81 om small clinical trials have suggested that estrogen replacement therapy may be useful for the treat

82 rmed the suggestion from animal studies that estrogen replacement therapy may have an inverse relatio

83 Epidemiologic studies have suggested that estrogen replacement therapy may lower the risk of osteo

84 Recent studies indicate that postmenopausal estrogen replacement therapy may prevent or delay the on

85 tion of Abeta40/42 peptides, suggesting that estrogen replacement therapy may protect women against t

86 ent study do not support the hypothesis that estrogen replacement therapy may slow age-related cognit

87 reast cancer, and that alcohol combined with estrogen replacement therapy may synergistically enhance

88 Observational studies have suggested that estrogen-replacement therapy may reduce a woman's risk o

89 logical data suggest a protective effect for estrogen replacement therapy on colon cancer.

90 e of this study was to assess the effects of estrogen replacement therapy on long-term outcome, inclu

91 The effects of estrogen replacement therapy on prognosis in women with

92 trials have mainly focused on the effect of estrogen replacement therapy on the primary and secondar

93 enopausal women, whether they were receiving estrogen-replacement therapy or not.

94 ngs that adding progestins to postmenopausal estrogen replacement therapy protects against endometria

95 l epidemiological studies have reported that estrogen replacement therapy protects against the develo

96 Short-term estrogen replacement therapy restored trkA mRNA expressi

97 In contrast, estrogen replacement therapy significantly increased med

98 Estrogen replacement therapy significantly increased med

99 This study demonstrates the potential for estrogen replacement therapy to reduce angiographic meas

100 he relation of endogenous estrogen levels or estrogen replacement therapy to the risk of poor cogniti

101 establishing the initiation and duration of estrogen replacement therapy use as a means to prevent c

102 the combination of higher breast density and estrogen replacement therapy use.

103 ed with the combination of dense breasts and estrogen replacement therapy use; there was little diffe

104 for nondense breasts and 74% (180 of 244) in estrogen replacement therapy users and 81% (417 of 513)

105 ommendations in women aged 40-49 years or in estrogen replacement therapy users.

106 available regarding the relative benefits of estrogen replacement therapy versus reductase inhibitors

107 all-cause mortality associated with current estrogen replacement therapy was 0.50 (95% CI 0.25-1.00)

108 s 0.50 (95% CI 0.25-1.00), and that for past estrogen replacement therapy was 0.79 (95% CI 0.56-1.09)

109 interval (CI) 0.32-1.30), and that for past estrogen replacement therapy was 0.90 (95% CI 0.62-1.31)

110 Estrogen replacement therapy was associated with an impr